Zymeworks ZYME Exchangeable shares, no par value, 550,884 and 553,184 issued and outstanding shares at March 31, 2026 and December 31, 2025, respectively
Exchangeable shares, no par value, 550,884 and 553,184 issued and outstanding shares at March 31, 2026 and December 31, 2025, respectively at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept zyme:ExchangeableSharesValueIssued.
The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zymeworks's exchangeable shares, no par value, 550,884 and 553,184 issued and outstanding shares at march 31, 2026 and december 31, 2025, respectively.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zymeworks's exchangeable shares, no par value, 550,884 and 553,184 issued and outstanding shares at march 31, 2026 and december 31, 2025, respectively?
- Zymeworks (ZYME) reported exchangeable shares, no par value, 550,884 and 553,184 issued and outstanding shares at march 31, 2026 and december 31, 2025, respectively of $7.91M in Q1 2026.
- How has Zymeworks's exchangeable shares, no par value, 550,884 and 553,184 issued and outstanding shares at march 31, 2026 and december 31, 2025, respectively changed year-over-year?
- Zymeworks's exchangeable shares, no par value, 550,884 and 553,184 issued and outstanding shares at march 31, 2026 and december 31, 2025, respectively decreased by 3.3% year-over-year, from $8.18M to $7.91M.
- What does exchangeable shares, no par value, 550,884 and 553,184 issued and outstanding shares at march 31, 2026 and december 31, 2025, respectively mean?
- This represents the carrying value of equity instruments that grant holders the right to exchange them for common shares or other assets under specific conditions. These shares function as a form of hybrid capital, reflecting the company's historical financing structure and potential future dilution. It is a critical component for assessing the total equity base and the potential impact on shareholder ownership stakes.